BIOLASE Stock Price, News & Analysis (NASDAQ:BIOL) $1.51 +0.36 (+31.30%) (As of 12/4/2023 ET) Add Compare Share Share Today's Range$1.19▼$1.6550-Day Range$1.09▼$1.8952-Week Range$1.07▼$88.66Volume2.25 million shsAverage Volume165,936 shsMarket Capitalization$3.47 millionP/E RatioN/ADividend YieldN/APrice Target$77.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media BIOLASE MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside4,999.3% Upside$77.00 Price TargetShort InterestBearish5.10% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.18Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.79 out of 5 stars 3.5 Analyst's Opinion Consensus RatingBIOLASE has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $77.00, BIOLASE has a forecasted upside of 4,999.3% from its current price of $1.51.Amount of Analyst CoverageBIOLASE has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.10% of the float of BIOLASE has been sold short.Short Interest Ratio / Days to CoverBIOLASE has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BIOLASE has recently increased by 1,068.60%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBIOLASE does not currently pay a dividend.Dividend GrowthBIOLASE does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BIOL. Previous Next 2.3 News and Social Media Coverage News SentimentBIOLASE has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for BIOLASE this week, compared to 1 article on an average week.Search Interest5 people have searched for BIOL on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added BIOLASE to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BIOLASE insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.27% of the stock of BIOLASE is held by insiders. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of BIOLASE is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BIOLASE is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBIOLASE has a P/B Ratio of 0.02. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About BIOLASE Stock (NASDAQ:BIOL)BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, hygiene, therapy pain relief, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces; and sells teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.Read More BIOL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BIOL Stock News HeadlinesNovember 30, 2023 | americanbankingnews.comBIOLASE (NASDAQ:BIOL) Lowered to "Sell" at StockNews.comNovember 15, 2023 | markets.businessinsider.comPositive Clinical Trial Results and Successful Cost Optimization Initiatives Bolster Buy Rating for Biolase Despite Lowered Price TargetDecember 5, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 10, 2023 | markets.businessinsider.comPositive McGuire Study Results Boost Biolase’s Market Potential and Justify Buy RatingNovember 10, 2023 | msn.comBiolase, Adaptive Biotechnologies among healthcare moversNovember 9, 2023 | msn.comBiolase GAAP EPS of -$3.89 misses by $2.04, revenue of $10.92M misses by $2.29MNovember 9, 2023 | finance.yahoo.comBIOLASE REPORTS THIRD QUARTER FINANCIAL RESULTS; COMPANY BENEFITTING FROM STRATEGIC ACTIONS TAKEN TO STREAMLINE OPERATIONS AND GAIN GREATER OPERATIONAL EFFICIENCIESNovember 8, 2023 | benzinga.comA Preview Of Biolase's EarningsDecember 5, 2023 | Edge On The Street (Ad)U.S. Military Defense Fails Without Vanadium?The metal vanadium is needed for numerous military applications, including jet engines, airframes, and ballistic missiles. And although the U.S. Govt. considers vanadium critical to national security, less than 5% of the metal is mined in America. This means we're at the mercy of China and Russia for our supply. November 8, 2023 | finance.yahoo.comLandmark Study Performed by the Independent McGuire Institute Confirms Positive 12 Month Clinical Outcomes for BIOLASE REPAIR® Perio ProtocolNovember 7, 2023 | finance.yahoo.comBIOLASE TO REPORT THIRD QUARTER 2023 RESULTS ON NOVEMBER 9, 2023November 1, 2023 | morningstar.comBiolase Inc BIOLOctober 18, 2023 | ca.finance.yahoo.comBIOLASE, Inc. (BIOL)September 18, 2023 | finance.yahoo.comBIOLASE Inc. Announces Closing of $4.5 Million Underwritten Public Offering of Series J Convertible Redeemable Preferred Stock and WarrantsSeptember 15, 2023 | benzinga.comHere's Why BIOLASE Shares Were Volatile This WeekSeptember 14, 2023 | benzinga.comWhy BIOLASE Stock Is Getting Obliterated ThursdaySeptember 14, 2023 | msn.comBIOLASE down 30%, prices $4.5M stock offeringSeptember 14, 2023 | marketwatch.comBiolase Shares Plummet After Offering PricesSeptember 13, 2023 | finance.yahoo.comBIOLASE Inc. Announces Pricing of $4.5 Million Underwritten Public Offering of Series J Convertible Redeemable Preferred Stock and WarrantsAugust 11, 2023 | finanznachrichten.deBIOLASE, Inc.: Biolase Reports Record Consumable Sales As Total Second Quarter Revenue Increases 17% Year Over YearAugust 11, 2023 | finance.yahoo.comQ2 2023 BIOLASE Inc Earnings CallAugust 11, 2023 | msn.comBiolase Non-GAAP EPS of -$4.24 beats by $1.76, revenue of $14.3M misses by $1.06MAugust 11, 2023 | sfgate.comBiolase: Q2 Earnings SnapshotAugust 11, 2023 | finance.yahoo.comBIOLASE REPORTS RECORD CONSUMABLE SALES AS TOTAL SECOND QUARTER REVENUE INCREASES 17% YEAR OVER YEARAugust 10, 2023 | finance.yahoo.comBIOLASE, Inc. (BIOL) Interactive Stock Chart - Yahoo FinanceAugust 9, 2023 | markets.businessinsider.comHere's what Wall Street expects from Biolase's earnings reportAugust 3, 2023 | finance.yahoo.comBIOLASE TO REPORT SECOND QUARTER 2023 RESULTS ON AUGUST 10, 2023See More Headlines Receive BIOL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BIOLASE and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2023Today12/05/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Dental equipment & supplies Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BIOL Previous SymbolNASDAQ:BLTI CUSIPN/A CIK811240 Webwww.biolase.com Phone(949) 361-1200Fax949-273-6677Employees188Year FoundedN/APrice Target and Rating Average Stock Price Target$77.00 High Stock Price Target$150.00 Low Stock Price Target$4.00 Potential Upside/Downside+4,999.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($158.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,630,000.00 Net Margins-50.61% Pretax Margin-50.34% Return on Equity-503.34% Return on Assets-63.51% Debt Debt-to-Equity Ratio34.06 Current Ratio1.40 Quick Ratio0.71 Sales & Book Value Annual Sales$48.46 million Price / Sales0.07 Cash FlowN/A Price / Cash FlowN/A Book Value$63.32 per share Price / Book0.02Miscellaneous Outstanding Shares2,300,000Free Float2,291,000Market Cap$3.47 million OptionableNot Optionable Beta1.16 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. John R. Beaver (Age 62)President, CEO & Director Comp: $592.47kMs. Jennifer Bright (Age 51)Chief Financial Officer Comp: $351.06kMr. Steven Sandor (Age 42)Chief Operating Officer Comp: $299.43kDr. Russell Morrow D.D.S.Chief Dental OfficerMr. Michael C. Carroll (Age 51)Corporate Secretary Key CompetitorsSonendoNYSE:SONXThermoGenesisNASDAQ:THMONovanNASDAQ:NOVNDynatronicsNASDAQ:DYNTPolyPidNASDAQ:PYPDView All CompetitorsInsiders & InstitutionsWalleye Capital LLCSold 1,403,565 shares on 11/21/2023Ownership: 0.736%Education Foundation SchulerBought 13,079 shares on 2/11/2023Total: $797,819.00 ($61.00/share)Jonathan T Md LordSold 35 sharesTotal: $2,625.00 ($75.00/share)View All Insider TransactionsView All Institutional Transactions BIOL Stock Analysis - Frequently Asked Questions Should I buy or sell BIOLASE stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIOLASE in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BIOL shares. View BIOL analyst ratings or view top-rated stocks. What is BIOLASE's stock price target for 2024? 2 Wall Street analysts have issued 12-month price targets for BIOLASE's stock. Their BIOL share price targets range from $4.00 to $150.00. On average, they anticipate the company's share price to reach $77.00 in the next twelve months. This suggests a possible upside of 4,999.3% from the stock's current price. View analysts price targets for BIOL or view top-rated stocks among Wall Street analysts. How have BIOL shares performed in 2023? BIOLASE's stock was trading at $65.00 on January 1st, 2023. Since then, BIOL stock has decreased by 97.7% and is now trading at $1.51. View the best growth stocks for 2023 here. Are investors shorting BIOLASE? BIOLASE saw a increase in short interest in November. As of November 15th, there was short interest totaling 100,500 shares, an increase of 1,068.6% from the October 31st total of 8,600 shares. Based on an average trading volume of 309,600 shares, the days-to-cover ratio is currently 0.3 days. Approximately 5.1% of the shares of the stock are short sold. View BIOLASE's Short Interest. When is BIOLASE's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024. View our BIOL earnings forecast. How were BIOLASE's earnings last quarter? BIOLASE, Inc. (NASDAQ:BIOL) released its quarterly earnings results on Thursday, November, 9th. The medical technology company reported ($3.89) earnings per share (EPS) for the quarter. The medical technology company earned $10.92 million during the quarter. BIOLASE had a negative trailing twelve-month return on equity of 503.34% and a negative net margin of 50.61%. When did BIOLASE's stock split? BIOLASE's stock reverse split on Friday, July 28th 2023. The 1-100 reverse split was announced on Friday, July 28th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. What is John R. Beaver's approval rating as BIOLASE's CEO? 4 employees have rated BIOLASE Chief Executive Officer John R. Beaver on Glassdoor.com. John R. Beaver has an approval rating of 13% among the company's employees. This puts John R. Beaver in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 35.0% of employees surveyed would recommend working at BIOLASE to a friend. What other stocks do shareholders of BIOLASE own? Based on aggregate information from My MarketBeat watchlists, some companies that other BIOLASE investors own include Himax Technologies (HIMX), Accelerate Diagnostics (AXDX), Biocept (BIOC), Magnachip Semiconductor (MX), Fluidigm (FLDM), Matinas BioPharma (MTNB), MicroVision (MVIS), Acasti Pharma (ACST), Bionano Genomics (BNGO) and Genius Brands International (GNUS). Who are BIOLASE's major shareholders? BIOLASE's stock is owned by many different institutional and retail investors. Top institutional shareholders include Walleye Capital LLC (0.74%). Insiders that own company stock include Education Foundation Schuler, John R Beaver, John R Beaver and Jonathan T Md Lord. View institutional ownership trends. How do I buy shares of BIOLASE? Shares of BIOL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:BIOL) was last updated on 12/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BIOLASE, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.